Sustained improvement in depression seen in study of esketamine nasal spray
The Brown University Psychopharmacology Update September 1, 2023 DOI: 10.1002/pu.31058 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression |
| Intervention | Esketamine nasal spray |
| Topics | Depression Esketamine |
| Key points | Interim results from a Phase 3 trial indicate that esketamine nasal spray produced no emerging safety concerns and sustained improvement in depressive symptoms, with nearly half of participants meeting criteria for remission by the end of the optimization/maintenance phase. |
Abstract
Interim results from a Phase 3 study of esketamine nasal spray in patients with treatment‐resistant depression showed no emerging safety concerns and sustained improvement in depressive symptoms. Nearly half of study participants met criteria for remission at the end of the study's optimization/maintenance phase, the investigators reported. Study results were published online May 12, 2023, in Neuropsychopharmacology.